Psoralen
Based on 7 publication(s) in Google Scholar
Psoralen (Ficusin) is a coumarin isolated from the seeds of Fructus Psoraleae. Psoralen exhibits a wide range of biological properties, including anti-cancer, antioxidant, antidepressant, anticancer, antibacterial, and antiviral, et al.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.96%
- CAS No.: 66-97-7
- Formule: C11H6O3
- Masse moléculaire:186.16
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Psoralen
More- Anal Chem. 2022 Oct 4;94(39):13623-13630. [Abstract]
- J Ethnopharmacol. 2022 Nov 15:298:115593. [Abstract]
- Biomedicines. 2024 Dec 31;13(1):73. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
- Curr Proteomics. 2026 Jul 11;23(4):100129.
- Evid Based Complement Alternat Med. 2022 Aug 27:2022:1952891. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
-
WB
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| B16 | IC50 |
>200 μg/mL
Compound: 7
|
Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs
Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs
|
[PMID: 22450129] |
| HCT-116 | IC50 |
45.6 μM
Compound: 5
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| HEK293 | IC50 |
>167 μM
Compound: 3
|
Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay
Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay
|
[PMID: 20558060] |
| HL-60 | IC50 |
16 μM
Compound: 1
|
Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM
Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM
|
[PMID: 15837311] |
| HT-29 | IC50 |
41.7 μM
Compound: 5
|
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| K562 | IC50 |
>10 μM
Compound: 20
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| K562 | IC50 |
131 μM
Compound: 5
|
Cytotoxicity against human K562 cells after 96 hrs by MTT assay
Cytotoxicity against human K562 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| LoVo | IC50 |
16 μM
Compound: 1
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM
|
[PMID: 15837311] |
In Vitro
Psoralen (10-500 μM; 24-48 hours) inhibits cell viability in a concentration- and time-dependent manner in L02 and?HepG2 cells. In L02 cells, Psoralen at 400 μM does not significantly change extracellular LDH levels, and 400 μM or 450 μM psoralen inhibits 50–60% of cell viability[1].Psoralen (150-450 μM; 24 hours) induces significant S-phase arrest in L02 cells in time- and dose-dependent manners, but it does not exhibits significant change in the cycle distribution of HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:L02 and HepG2 cells
-
Concentration:10 μM, 50 μM,100 μM, 200 μM, 300 μM,400 μM,450 μM,500 μM
-
Incubation Time:24 or 48 hours
-
Result:Inhibited the viability of L02 and HepG2 cells mainly by suppressing cell proliferation rather than causing cell death.
-
Cell Line:L02 and HepG2 cells
-
Concentration:150 μM; 300 μM; 450 μM
-
Incubation Time:24 or 48 hours
-
Result:Induced cell S-phase arrest instead of causing cell apoptosis or death.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude (BALB/c nu/nu) mice[2]
-
Dosage:17.5 mg/kg
-
Administration:Oral gavage; 17.5 mg/kg; 6 weeks
-
Result:Inhibited metastasis of breast cancer to bone in vivo.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 66-97-7
-
Appearance Solid
-
Masse moléculaire 186.16
-
Formule C11H6O3
-
Color White to off-white
-
SMILES
O=C1C=CC2=CC3=C(OC=C3)C=C2O1
-
Synonyms
Ficusin
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Force-Dependent Intercalative Bulky DNA Adduct Formation Detected by Single-Molecule Stretching. [Abstract]2022 Oct 4;94(39):13623-13630. PMID: 36129494 -
J Ethnopharmacol
2022 Nov 15:298:115593. PMID: 35973629 -
Biomedicines
Comparison of Radio- and Phototoxicity in Association with an Enhancing Effect of the Photosensitizers Psoralen, Trioxsalen and Ortho-Iodo-Hoechst33258 on FaDu, PC-3, 4T1 and B16-F10 Cells. [Abstract]2024 Dec 31;13(1):73. PMID: 39857658
Psoralen purchased from MedChemExpress. Usage Cited in: Biomedicines. 2024 Dec 31;13(1):73. [Abstract]
Nuclear staining of 4T1 with Pso (Psoralen) (10 nM; 1 h).
Psoralen purchased from MedChemExpress. Usage Cited in: Biomedicines. 2024 Dec 31;13(1):73. [Abstract]
The combination of Pso (Psoralen) (10 nM; 1 h) and 3 J/cm2 UVA had the greatest effect at B16-F10 with a 2.04-fold increase (p < 0.005).
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
In Vivo
Mitochondrial Damage-induced Ferroptosis: The Molecular Mechanism by Which Psoralen Inhibits the Proliferation and Invasion of Non-small-cell Lung Cancer Cells. [Abstract]2025 Sep-Oct;39(5):2681-2702. PMID: 40877163
Psoralen purchased from MedChemExpress. Usage Cited in: In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
Cell viability of A549 cells treated with different concentrations of Psoralen (20-160 μg/mL) for 12, 24, and 48 h, measured using the CCK-8 assay.
Psoralen purchased from MedChemExpress. Usage Cited in: In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
Effects of Psoralen (15-60 μg/mL) on A549 cell proliferation, assessed by the 5-ethynyl-2'-deoxyuridine (EdU) incorporation assay.
Psoralen purchased from MedChemExpress. Usage Cited in: In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
Wound healing assay assessing the effect of different Psoralen (15-60 μg/mL) concentrations on A549 cell migration. Red lines indicate the wound edges, showing the extent of cell migration at different time points across treatment groups.
Psoralen purchased from MedChemExpress. Usage Cited in: In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
Psoralen (15-60 μg/mL; 24 h) increases intracellular Fe2+ levels in A549 cells.
Psoralen purchased from MedChemExpress. Usage Cited in: In Vivo. 2025 Sep-Oct;39(5):2681-2702. [Abstract]
Psoralen (15-60 μg/mL; 24 h) disrupts antioxidant defense and enhances lipid peroxidation in A549 cells. Western blot analysis of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) protein expression levels in A549 cells treated with psoralen psoralen , with quantitative analysis.
-
-
Evid Based Complement Alternat Med
The In Vitro Effect of Psoralen on Glioma Based on Network Pharmacology and Potential Target Research. [Abstract]2022 Aug 27:2022:1952891. PMID: 36065261
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (537.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (13.43 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Li Yin, et al. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med. 2018 Jun;41(6):3727-3735. [Content Brief]
[2]. Wu C, et al. Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia. 2013 Dec;91:205-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.3717 mL | 26.8586 mL | 53.7172 mL | 134.2931 mL |
| 5 mM | 1.0743 mL | 5.3717 mL | 10.7434 mL | 26.8586 mL | |
| 10 mM | 0.5372 mL | 2.6859 mL | 5.3717 mL | 13.4293 mL | |
| 15 mM | 0.3581 mL | 1.7906 mL | 3.5811 mL | 8.9529 mL | |
| 20 mM | 0.2686 mL | 1.3429 mL | 2.6859 mL | 6.7147 mL | |
| 25 mM | 0.2149 mL | 1.0743 mL | 2.1487 mL | 5.3717 mL | |
| 30 mM | 0.1791 mL | 0.8953 mL | 1.7906 mL | 4.4764 mL | |
| 40 mM | 0.1343 mL | 0.6715 mL | 1.3429 mL | 3.3573 mL | |
| 50 mM | 0.1074 mL | 0.5372 mL | 1.0743 mL | 2.6859 mL | |
| 60 mM | 0.0895 mL | 0.4476 mL | 0.8953 mL | 2.2382 mL | |
| 80 mM | 0.0671 mL | 0.3357 mL | 0.6715 mL | 1.6787 mL | |
| 100 mM | 0.0537 mL | 0.2686 mL | 0.5372 mL | 1.3429 mL |
Psoralen Related Classifications
HY-N0053 Related Classifications
Powered by Bioz